Effects of individualized homoeopathic medicine in rheumatoid arthritis patients.
Phase 3
- Conditions
- Health Condition 1: M069- Rheumatoid arthritis, unspecified
- Registration Number
- CTRI/2023/07/054644
- Lead Sponsor
- oble Homoeopathic College and Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Cases with Anti CCP above 20IU/ml or cases fulfilling the diagnostic criteria of rheumatoid arthritis.
Patients who had definite or classical RA, were seropositive for rheumatoid factor and were receiving either stable doses of single non-inflammatory drugs (NSAIDs) for more than 3 months or single disease-modifying anti-rheumatic drugs (DMARDs) with or without NSAIDs for more than 6 months.
Fully diagnosed case with adequate investigations
Exclusion Criteria
Patients who were severely disabled, had taken systemic steroids in the previous 6 months or had withdrawn from DMARD therapy in the previous 12 months were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess changes in reducing the symptoms of joint inflammation in rheumatoid arthritis by RASS through individualized homoeopathic treatment. <br/ ><br>Timepoint: Baseline, 4 weeks, 12 weeks, till 6th month <br/ ><br>
- Secondary Outcome Measures
Name Time Method To shortlist the commonly indicated homoeopathic medicines. <br/ ><br> <br/ ><br>To access weather any benefits from adjunctive homoeopathic intervention in patients with rheumatoid arthritis are due to homoeopathic remedies. <br/ ><br>Timepoint: Baseline, 4 weeks, 12 weeks, till 6th month